Sign in
Taking people in United StatesPhase 2

Soft palate surgery, acetazolamide and eszopiclone in obstructive sleep apnea

Tests acetazolamide and eszopiclone in people with obstructive sleep apnea.

Key facts

Who runs it
University of California, Los Angeles
Where
Santa Monica and Westwood, Los Angeles, United StatesSee the 2 sites
Trial code
Registry title
Endotypic Traits and Obstructive Sleep Apnea Surgery
Status
Recruiting
Phase
Phase 2
People taking part
150 people, planned
Started
7 Jan 2024
Expected to end
31 Aug 2028
Type of study
Interventional, 2 groups
Treatments tested
  • Acetazolamide 500 MG QHS
  • Eszopiclone 3 mg QHS
Record updated
1 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with moderate to severe obstructive sleep apnea who cannot use a breathing machine (CPAP) and plan soft palate surgery. It studies acetazolamide and eszopiclone.

Age
21 years or older.
Sex
All sexes can join.
Disease stage
Moderate to severe obstructive sleep apnea (obstructive AHI ≥ 15 events/hour). Central/mixed apnea index <5 events/hour. Tonsil size 0-2+. No complete tongue-related blockage on DISE (a sleep scope test). Body mass index <35 kg/m2.
Earlier treatment
People must not tolerate positive airway pressure (use < 2 hours/night at least 5 nights/week). They must not tolerate an oral appliance or be a poor candidate for one. They must have agreed to palate surgery as standard care. No prior throat surgery other than tonsillectomy. Medicines stable for ≥2 months. No hypnotics, anxiolytics, stimulants or sedating antidepressants.

Main reasons for not taking part

  • Allergy to the study drugs, or serious allergic reaction to sulfonamides.
  • Severe kidney or liver disease, electrolyte imbalance or adrenal insufficiency.
  • High-dose aspirin, ketoconazole or other strong CYP3A4 inhibitors.
  • Pregnancy, alcohol or substance abuse.
  • Neurologic, heart, lung or other sleep disorders, or a near-miss or car crash from sleepiness in the past 12 months.

The registry criteria, word for word

Show all 27 criteriaShow less

Who can take part

  • age ≥21 years
  • moderate to severe OSA (obstructive AHI ≥ 15 events/hour)
  • central/mixed apnea index <5 events/hour
  • intolerance of positive airway pressure (defined as use < 2 hours/night at least 5 nights/week)
  • intolerance or poor candidate for oral appliance
  • participant has provided informed consent for palate surgery as part of their standard of care
  • tonsil size 0-2+ (without markedly enlarged tonsils that have high surgical success rates)
  • DISE without evidence of complete tongue-related obstruction (reflecting poorer results with isolated palate surgery)
  • medications stable for ≥2 months
  • body mass index <35 kg/m2
  • absence of uncontrolled nasal obstruction
  • no prior pharyngeal surgery other than tonsillectomy
  • no neurologic, cardiac or pulmonary disorders
  • absence of psychiatric disorder except for treated depression or mild anxiety
  • no co-existing sleep disorder, such as narcolepsy, chronic insomnia, or restless legs syndrome
  • no use of hypnotics, anxiolytics, stimulants, or sedating antidepressants
  • no near-miss or prior motor vehicle crash due to sleepiness in past 12 months; and
  • <3 caffeinated beverages daily

Who cannot take part

  • subjects with prior serious allergic reaction (such as Stevens-Johnson syndrome) to sulfonamides
  • subjects who are on high-dose aspirin therapy due to risk of severe metabolic acidosis
  • subjects on ketoconazole or other strong CYP3A4 inhibitors (these will increase eszopiclone blood levels)
  • history of allergic reaction to either of the study drugs
  • subjects with a history of hypersensitivity to either of the two study drugs
  • subjects with severe kidney disease or severe liver disease
  • subjects with a history of electrolyte imbalance or adrenal insufficiency (due to risks related to acetazolamide)
  • pregnancy; and
  • alcohol or substance abuse

Where in United States

  • UCLA Santa Monica Medical CenterSanta Monica, United StatesContact: Eric Kezirian, MD, MPHTaking people
  • UCLA WestwoodWestwood, Los Angeles, United StatesContact: Eric Kezirian, MD, MPHNot yet recruiting

About the trial

What the trial wants to find out

This study will examine factors associated with outcomes after soft palate surgery and medications (acetazolamide, eszopiclone) that may treat other potential causes of obstructive sleep apnea (loop gain, arousal threshold).

The 2 groups in the trial

  • AcetazolamideTreatment being tested

    Treatment with acetazolamide 500 mg nightly for 1 month.

    Treatment: Acetazolamide 500 MG QHS

  • Acetazolamide/EszopicloneTreatment being tested

    Treatment with acetazolamide 500 mg and eszopiclone 3 mg nightly for 1 month.

    Treatment: Acetazolamide 500 MG QHS and Eszopiclone 3 mg QHS

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Endotypic Traits and Obstructive Sleep Apnea Surgery
Plain-language title
Soft palate surgery, acetazolamide and eszopiclone in obstructive sleep apneaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
1 July 2026